BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld MedTech
Home
» Diasorin to acquire Focus assets from Quest Diagnostics for $300 million
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Diasorin to acquire Focus assets from Quest Diagnostics for $300 million
March 31, 2016
By
Omar Ford
No Comments
Saluggia, Italy-based, Diasorin S.p.A. said it will acquire Focus Diagnostics Inc.'s immunodiagnostic and molecular diagnostic products for $300 million in cash from Madison, N.J.-based, Quest Diagnostics Inc.
BioWorld MedTech